Radiation induces an EGFR-dependent lactate-epigenetic program underlying synergy with EGFR inhibition

Hongxia Cheng1, Lu Meng1, Shilan Luo1

  • 1Department of Radiation Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Abstract

Insights

The EGFR T790M mutation amplifies glycolysis, leading to lactate buildup that shields tumors from radiation therapy by promoting DNA repair. Targeting this metabolic pathway restores radiosensitivity and improves treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Clinical synergy between EGFR-TKIs and radiotherapy is observed.
  • Mechanisms of this synergy are unclear, especially in EGFR T790M-mutant tumors.

Purpose of the Study:

  • Investigate radiation responses in EGFR T790M-mutant tumors.
  • Elucidate molecular mechanisms of therapeutic synergy between EGFR-TKIs and radiotherapy.

Main Methods:

  • Utilized EGFR T790M-positive cell lines, organoids, and xenografts.
  • Performed metabolic profiling, protein analyses, ChIP-seq, and DNA repair assessments.

Main Results:

  • EGFR T790M drives radiation-amplified glycolysis and intracellular lactate accumulation.
  • Lactate promotes histone lactylation, enhancing DNA repair gene expression and facilitating DNA damage resolution.
  • Disrupting the LDHA-lactate axis restores radiosensitivity and improves radiotherapy efficacy in preclinical models.

Conclusions:

  • Identified a metabolic-epigenetic-repair axis driving radiotherapy resistance in EGFR T790M tumors.
  • Redefined the role of EGFR T790M in radiation biology.
  • Provided a framework for metabolism-informed combination radiotherapy strategies.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...